Trends in decision-making process for pharmaceuticals in Western European countries

Abstract

Health care financing has become a topic on the political agenda in Western Europe in recent decades.For every government it has become a subject of continuous concern because the costs of health services and health care are an increasing important part of the collective burden of the economy.Most cost containment measures have relied on budgeting or price controls.Because those traditional central cost containment measures were only partially successful, due to lack of incentives, the health authorities in Europe started to establish incentives for efficient health care delivery by means of decentralisation of the health care decision-making process and the implementation of market mechanisms.Both traditional and recent containment measures focus especially on the pharmaceutical drugs sector in many countries.Recently there have been three parallel trends showing increasing data requirements at a central level, more decentralisation of the responsibilities and decision-making process and prescription restrictions.We address especially the increasing central data requirements and decentralisation of the pricing and/or reimbursement decision-making process.At a central level the demand is increasing for cost-effectiveness and budgetary impact data, which has already resulted in formal reporting requirements in some countries. The findings are based on the literature and Original papers HEPAC 2001 · 2:162-169

Cost Containment Measures for Pharmaceuticals Expenditure in the EU Countries: A Comparative Analysis

“…A positive list contains the drugs that will receive different levels of reimbursement, while the drugs on the negative list must be paid entirely by the patient [7]. Except for Finland and the UK, who have negative lists, the other EU countries, have a positive list.…”

The economic burden of supportive care of cancer patients

“…Economic evaluations, including cost-effectiveness/utility analysis, budget impact analysis, or other forms, have been used to assist reimbursement decisions for new treatments in Australia and Canada since the early 1990s [20]. Some European countries (e.g., UK, Finland, and Portugal) have begun to incorporate economic data in reimbursement decisions [46] and many other countries plan to do so in the near future. …”

Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: A time-series analysis for France 1998–2010

“…Most of the growth may be explained by changes in practices for a given morbidity, driven by the prescription of more innovative drugs [1]. This rise in expenditures has resulted in policies aimed at either reducing the use of pharmaceuticals or steering patients to using less expensive alternatives [2][3][4][5]. Increasing the patient's out-of-pocket payment is commonly used to contain pharmaceutical spending.…”